MDxHealth, University Hospital Bonn deal

The university will use MDxHealth's PredictMDx for Glioblastoma to screen patients for the university's Phase III CeTeG trial, which will enroll patients with a methylated O-6-methylguanine DNA methyltransferase ( MGMT) gene. This month, the university will begin the trial in newly diagnosed patients with glioblastoma multiforme (GBM) to evaluate the addition of lomustine to temozolomide and radiotherapy, the standard of care. PredictMDx for Glioblastoma is an assay for determining the methylation status of the MGMT gene to identify patients that are most likely to benefit from treatment with alkylating agents. Terms were not disclosed. ...